Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adaptimmune Ther Ads (ADAP)

Adaptimmune Ther Ads (ADAP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 392,591
  • Shares Outstanding, K 104,691
  • Annual Sales, $ 59,510 K
  • Annual Income, $ -95,510 K
  • 60-Month Beta 1.47
  • Price/Sales 208.90
  • Price/Cash Flow N/A
  • Price/Book 2.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.33
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.36
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.62 +3.59%
on 01/27/20
4.65 -19.35%
on 02/05/20
-0.39 (-9.42%)
since 01/21/20
3-Month
0.79 +374.68%
on 11/22/19
6.00 -37.50%
on 01/14/20
+2.93 (+357.15%)
since 11/21/19
52-Week
0.71 +428.91%
on 11/15/19
6.00 -37.50%
on 01/14/20
-0.91 (-19.53%)
since 02/21/19

Most Recent Stories

More News
Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for the Full Year / Fourth Quarter 2019 and provide a business update, before the U.S....

ADAP : 3.75 (-5.06%)
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Gavin Wood as Chief Financial Officer (CFO), effective April 1, 2020.

ADAP : 3.75 (-5.06%)
ABC : 97.00 (+0.49%)
AFFX : 14.01 (+0.14%)
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters' Option to Purchase Additional American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune") (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000...

ADAP : 3.75 (-5.06%)
Has Adaptimmune Therapeutics (ADAP) Outpaced Other Medical Stocks This Year?

Is (ADAP) Outperforming Other Medical Stocks This Year?

ADAP : 3.75 (-5.06%)
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Adaptimmune Therapeutics plc (ADAP).

ADAP : 3.75 (-5.06%)
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American...

ADAP : 3.75 (-5.06%)
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary...

ADAP : 3.75 (-5.06%)
Top Ranked Momentum Stocks to Buy for January 22nd

Top Ranked Momentum Stocks to Buy for January 22nd

CDLX : 95.87 (-3.04%)
AMK : 31.75 (-1.27%)
ADAP : 3.75 (-5.06%)
AAPL : 313.05 (-2.26%)
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares ("ADSs") in an underwritten public...

ADAP : 3.75 (-5.06%)
What Makes Adaptimmune Therapeutics PLC (ADAP) a New Buy Stock

Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ADAP : 3.75 (-5.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade ADAP with:

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

2nd Resistance Point 4.10
1st Resistance Point 3.93
Last Price 3.75
1st Support Level 3.62
2nd Support Level 3.48

See More

52-Week High 6.00
Fibonacci 61.8% 3.98
Last Price 3.75
Fibonacci 50% 3.35
Fibonacci 38.2% 2.73
52-Week Low 0.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar